高级检索
当前位置: 首页 > 详情页

HESPERIDIN PRETREATMENT PROTECTS HYPOXIA-ISCHEMIC BRAIN INJURY IN NEONATAL RAT

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China [2]Department of Pediatrics, Xiangyang Central Hospital, Xiangyang 441021, China [3]Department of Orthopedic, Xiangyang Central Hospital, Xiangyang 441021, China [4]Department of Pharmaclogy , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
出处:
ISSN:

关键词: hypoxia-ischemia encephalopathy hesperidin reactive oxygen species

摘要:
Neonatal hypoxia-ischemic encephalopathy (HIE) remains a major cause of brain damage, leading to high disability and mortality rates in neonates. In vitro studies have shown that hesperidin, a flavanone glycoside found abundantly in citrus fruits, acts as an antioxidant. Although hesperidin has been considered as a potential treatment for HIE, its effects have not been fully evaluated. In this study, the protective effect of hesperidin pretreatment against hypoxia-ischemic (HI) brain injury and possible signal pathways were investigated using in vivo and in vitro models. In vivo HI model employed unilateral carotid ligation in postnatal day 7 rat with exposure to 8% hypoxia for 2.5 h, whereas in vitro model employed primary cortical neurons of neonatal rats subjected to oxygen and glucose deprivation for 2.5 h. Hesperidin pretreatment significantly reduced Hl-induced brain tissue loss and improved neurological outcomes as shown in 2,3,5-triphenyltetrazolium chloride monohydrate staining and foot-fault results. The neuropro-tective effects of hesperidin are likely the results of preventing an increase in intracellular reactive oxygen species and lipid peroxide levels. Hesperidin treatment also activated a key survival signaling kinase, Akt, and suppressed the P-FoxO3 level. Hesperidin pretreatment protected neonatal HIE by reducing free radicals and activating phosphorylated Akt.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 3 区 医学
小类 | 3 区 神经科学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 神经科学
JCR分区:
出版当年[2011]版:
Q2 NEUROSCIENCES
最新[2023]版:
Q2 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者单位: [1]Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
通讯作者:
通讯机构: [4]Department of Pharmaclogy , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China [*1]1095 Jiefang Avenue, Tongji Hospital, Wuhan 430030, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:2 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)